Journal of Antimicrobial Chemotherapy (2000) 46, 437-442
© 2000 The British Society for Antimicrobial Chemotherapy
Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis
Department of Medicine, Santa Clara Valley Medical Center and California Institute for Medical Research, San Jose, California and the Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
The possible enhancement, using immunotherapy with interferon-gamma (IFN-
), combined with conventional antifungal therapy, was studied in a murine model of systemic cryptococcosis. Four weeks after intravenous challenge, infection was quantified in brains and livers of survivors. Groups received IFN- every other day beginning 7 days before (prophylaxis), or after infection (14 doses), or amphotericin B post-infection, or combinations of these regimens. IFN- alone was modestly effective, but impressively and significantly potentiated amphotericin in reducing infection in the most important site of infection, the brain. The efficacy was seen after lethal and non-lethal challenges, and when IFN- was given by the intravenous or subcutaneous routes. In non-lethal infection, only the combination amphotericin–IFN- resulted in sterilization of the central nervous system. Potentiation of fluconazole was less impressive. Adding prophylactic IFN- doses to IFN- therapy did not consistently enhance the therapeutic effect. These results suggest IFN- may have a role in potentiating conventional antifungal therapy of cryptococcosis.
* Correspondence address. Division of Infectious Diseases, Department of Medicine, Santa Clara Valley Medical Center, 751 S. Bascom Avenue, San Jose, CA 95128-2699, USA. Tel: +1-408-885-4303; Fax: +1-408-885-4306; E-mail: stevens{at}leland.stanford.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Voelz, D. A. Lammas, and R. C. May Cytokine Signaling Regulates the Outcome of Intracellular Macrophage Parasitism by Cryptococcus neoformans Infect. Immun., August 1, 2009; 77(8): 3450 - 3457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. L. Wormley Jr., J. R. Perfect, C. Steele, and G. M. Cox Protection against Cryptococcosis by Using a Murine Gamma Interferon-Producing Cryptococcus neoformans Strain Infect. Immun., March 1, 2007; 75(3): 1453 - 1462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Zhou, R. A. Gault, T. R. Kozel, and W. J. Murphy Immunomodulation with CD40 Stimulation and Interleukin-2 Protects Mice from Disseminated Cryptococcosis Infect. Immun., April 1, 2006; 74(4): 2161 - 2168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Lindell, T. A. Moore, R. A. McDonald, G. B. Toews, and G. B. Huffnagle Generation of Antifungal Effector CD8+ T Cells in the Absence of CD4+ T Cells during Cryptococcus neoformans Infection J. Immunol., June 15, 2005; 174(12): 7920 - 7928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. L. Maffei, L. F. Mirels, R. A. Sobel, K. V. Clemons, and D. A. Stevens Cytokine and Inducible Nitric Oxide Synthase mRNA Expression during Experimental Murine Cryptococcal Meningoencephalitis Infect. Immun., April 1, 2004; 72(4): 2338 - 2349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. V. Clemons, J. E. Lutz, and D. A. Stevens Efficacy of Recombinant Gamma Interferon for Treatment of Systemic Cryptococcosis in SCID Mice Antimicrob. Agents Chemother., March 1, 2001; 45(3): 686 - 689. [Abstract] [Full Text]
|
|